Citadel Advisors’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$61.9M Sell
211,500
-243,800
-54% -$80.1M 0.01% 1163
2025
Q4
$160M Sell
455,300
-28,400
-6% -$9.6M 0.02% 594
2025
Q3
$156M Buy
483,700
+102,700
+27% +$31.9M 0.02% 594
2025
Q2
$148M Buy
381,000
+67,600
+22% +$27.2M 0.03% 528
2025
Q1
$136M Buy
313,400
+57,300
+22% +$23M 0.03% 526
2024
Q4
$94.5M Buy
256,100
+82,900
+48% +$34.7M 0.02% 770
2024
Q3
$90.1M Sell
173,200
-1,700
-1% -$908K 0.02% 760
2024
Q2
$94.8M Sell
174,900
-113,400
-39% -$59.9M 0.02% 714
2024
Q1
$149M Sell
288,300
-205,500
-42% -$102M 0.03% 498
2023
Q4
$233M Buy
493,800
+307,000
+164% +$142M 0.05% 295
2023
Q3
$81.3M Sell
186,800
-58,500
-24% -$26.5M 0.02% 741
2023
Q2
$109M Buy
245,300
+84,900
+53% +$39.2M 0.02% 564
2023
Q1
$73.8M Sell
160,400
-117,500
-42% -$55.9M 0.02% 793
2022
Q4
$143M Sell
277,900
-321,800
-54% -$163M 0.03% 481
2022
Q3
$272M Buy
599,700
+51,500
+9% +$24.6M 0.06% 207
2022
Q2
$265M Buy
548,200
+333,200
+155% +$165M 0.07% 199
2022
Q1
$106M Buy
215,000
+59,400
+38% +$27.2M 0.02% 634
2021
Q4
$72.1M Sell
155,600
-84,700
-35% -$35.6M 0.01% 891
2021
Q3
$89.6M Buy
240,300
+41,000
+21% +$15.6M 0.02% 719
2021
Q2
$76.1M Buy
199,300
+35,900
+22% +$13.7M 0.02% 831
2021
Q1
$58.7M Buy
163,400
+45,000
+38% +$14.5M 0.01% 921
2020
Q4
$38M Sell
118,400
-135,900
-53% -$41.7M 0.01% 1186
2020
Q3
$68.3M Buy
254,300
+25,800
+11% +$6.94M 0.02% 669
2020
Q2
$60.1M Sell
228,500
-39,000
-15% -$10.4M 0.02% 689
2020
Q1
$60.7M Sell
267,500
-4,600
-2% -$1.25M 0.03% 558
2019
Q4
$82.2M Sell
272,100
-15,300
-5% -$4.21M 0.04% 501
2019
Q3
$69M Sell
287,400
-23,800
-8% -$6.52M 0.03% 577
2019
Q2
$87.8M Buy
311,200
+131,300
+73% +$35.9M 0.04% 449
2019
Q1
$51.6M Sell
179,900
-11,400
-6% -$3.3M 0.03% 674
2018
Q4
$50.2M Sell
191,300
-94,100
-33% -$25.9M 0.03% 616
2018
Q3
$78.2M Buy
285,400
+160,800
+129% +$41.7M 0.03% 521
2018
Q2
$29.7M Sell
124,600
-4,100
-3% -$949K 0.01% 1000
2018
Q1
$28.3M Buy
128,700
+80,100
+165% +$18.8M 0.02% 881
2017
Q4
$10.9M Sell
48,600
-9,800
-17% -$2.09M 0.01% 1640
2017
Q3
$11.1M Buy
58,400
+3,800
+7% +$723K 0.01% 1509
2017
Q2
$10.3M Sell
54,600
-3,800
-7% -$683K 0.01% 1439
2017
Q1
$9.66M Sell
58,400
-20,200
-26% -$3.21M 0.01% 1470
2016
Q4
$11.3M Buy
78,600
+11,400
+17% +$1.53M 0.01% 1264
2016
Q3
$8.42M Buy
67,200
+2,500
+4% +$323K 0.01% 1518
2016
Q2
$8.5M Sell
64,700
-7,100
-10% -$971K 0.01% 1370
2016
Q1
$9.98M Sell
71,800
-25,800
-26% -$3.45M 0.01% 1197
2015
Q4
$13.6M Sell
97,600
-5,300
-5% -$730K 0.01% 1062
2015
Q3
$14.4M Buy
102,900
+22,500
+28% +$3.38M 0.01% 1113
2015
Q2
$13.2M Buy
80,400
+17,600
+28% +$2.81M 0.01% 1281
2015
Q1
$9.7M Sell
62,800
-16,600
-21% -$2.36M 0.01% 1485
2014
Q4
$9.98M Sell
79,400
-9,000
-10% -$1.11M 0.01% 1405
2014
Q3
$10.6M Buy
88,400
+20,100
+29% +$2.31M 0.01% 1324
2014
Q2
$7.35M Sell
68,300
-33,600
-33% -$3.46M 0.01% 1516
2014
Q1
$10.1M Buy
101,900
+7,700
+8% +$696K 0.01% 1253
2013
Q4
$8.7M Sell
94,200
-53,400
-36% -$4.74M 0.01% 1301
2013
Q3
$12.3M Sell
147,600
-18,700
-11% -$1.6M 0.02% 984
2013
Q2
$13.6M Buy
+166,300
New +$12.4M 0.02% 871

Other funds holding ELV

Citadel Advisors's ELV Position: Q1 2026 in Review

Citadel Advisors reduced its Elevance Health (ELV) stake by 6.3% in Q1 2026, selling an estimated $34.8M and leaving 1,562,219 shares worth $457M. The position accounts for 0.07% of the portfolio, ranked #199.

Citadel Advisors first reported a position in ELV in Q2 2013 and has held it in 49 quarters since. The position peaked at $585M in Q4 2025. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • Citadel Advisors held 1,562,219 shares of Elevance Health worth $457M as of Q1 2026.
  • Citadel Advisors sold 105,850 Elevance Health shares in Q1 2026, an estimated $34.8M.
  • Elevance Health made up 0.07% of Citadel Advisors's portfolio in Q1 2026, its #199 holding.
  • Citadel Advisors first reported a position in Elevance Health in Q2 2013 and has held it in 49 quarters since.
  • Citadel Advisors's Elevance Health position peaked at $585M in Q4 2025.
  • 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.